IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-80
SponsorUniversity of Florida
About this trial
This is a phase I study to assess the safety and feasibility of IL-8 receptor modified patient-derived activated CD70 CAR T cell therapy in CD70+ adult glioblastoma
Eligibility criteria
Qualifiers
Age ≥ 18 years
Newly-diagnosed de novo GBM based on the absence of previous history of brain tumor (WHO Grade IV glioma) by histopathology or molecular studies. (secondary GBM not eligible)
The tumor must have a supratentorial component
CD70 positive (≥5%, 1+)
Disqualifiers
Prior invasive malignancy (except for non-melanomatous skin cancer) unless disease free for ≥ 3years. (In situ cancer are permissible)
Metastases detected below the tentorium or beyond the cranial vault
Leptomeningeal disease beyond the cranial vault. (Focal, adjacent and leptomeningeal involvement is allowable at the discretion of the PI).
Recurrent or multifocal malignant gliomas.
Trial design
Treatments tested in this trial
- Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells
Treatment groups
39 Participants
are divided into 1 treatment groupSponsors and collaborators
University of Florida
Lead sponsor
AM Rosen Foundation
Collaborator
Source ClinicalTrials.gov